Data gathered: July 2
AI Stock Analysis - Allogene Therapeutics (ALLO)
Analysis generated February 28, 2025. Powered by Chat GPT.
Allogene Therapeutics is a biopharmaceutical company specializing in the research and development of allogeneic CAR T cell therapies for the treatment of cancer. The company's innovative approach aims to develop off-the-shelf CAR T cells that do not require individualized patient-specific production, thus potentially reducing costs and improving accessibility for cancer treatments.
Stock Alerts - Allogene Therapeutics (ALLO)
 |
Allogene Therapeutics | July 2 Price is up by 7.6% in the last 24h. |
|
Allogene Therapeutics | July 1 Price is up by 7.1% in the last 24h. |
|
Allogene Therapeutics | June 13 Insider Alert: MESSEMER DEBORAH M. is selling shares |
|
Allogene Therapeutics | June 6 Price is up by 7.8% in the last 24h. |
Download our app to get future alerts delivered in real-time.
Alternative Data for Allogene Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 2 | Sign up | Sign up | Sign up |
| Sentiment | 63 | Sign up | Sign up | Sign up |
| Webpage traffic | 16,000 | Sign up | Sign up | Sign up |
| Employee Rating | 88 | Sign up | Sign up | Sign up |
| Google Trends | 15 | Sign up | Sign up | Sign up |
| Patents | 33 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 16 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 3,199 | Sign up | Sign up | Sign up |
| Twitter Followers | 2,575 | Sign up | Sign up | Sign up |
| Twitter Mentions | 219 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 74 | Sign up | Sign up | Sign up |
| Linkedin Employees | 234 | Sign up | Sign up | Sign up |
About Allogene Therapeutics
Allogene Therapeutics is a clinical stage biotechnology company leading the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) products for cancer.
| Price | $1.20 |
| Target Price | Sign up |
| Volume | 4,810,000 |
| Market Cap | $258M |
| Year Range | $0.95 - $3.22 |
| Dividend Yield | 0% |
| Analyst Rating | 77% buy |
| Industry | Biotechnology |
In the news
 |
Exchange Traded Concepts LLC Purchases 8,183 Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO)June 25 - ETF Daily News |
|
Rhumbline Advisers Has $268,000 Stock Holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO)June 25 - ETF Daily News |
|
Brokerages Set Allogene Therapeutics, Inc. (NASDAQ:ALLO) Price Target at $8.44June 24 - ETF Daily News |
 |
Oncobiologics (NASDAQ:OTLK) versus Allogene Therapeutics (NASDAQ:ALLO) Financial ReviewJune 22 - ETF Daily News |
 |
Why Is Allogene Therapeutics (ALLO) Up 52.2% Since Last Earnings Report?June 12 - Yahoo |
|
What is Zacks Research’s Estimate for ALLO Q2 Earnings?June 6 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q1 '25 | 0 | 0 | 0 | -60M | 0 | -0.280 |
| Q4 '24 | 0 | 0 | 0 | -60M | -56M | -0.280 |
| Q3 '24 | 0 | 0 | 0 | -66M | -63M | -0.320 |
| Q2 '24 | 0 | 3.6M | -3.6M | -66M | -63M | -0.350 |
| Q1 '24 | 22,000 | 3.6M | 22,000 | -65M | -66M | -0.380 |
Insider Transactions View All
| MESSEMER DEBORAH M. filed to sell 107,431 shares at $1.4. June 12 '25 |
| Yoshiyama Annie filed to sell 130,663 shares at $1.4. April 23 '25 |
| Beneski Benjamin Machinas filed to sell 218,507 shares at $2. March 18 '25 |
| Chang David D filed to sell 5,276,569 shares at $2. March 18 '25 |
| MESSEMER DEBORAH M. filed to sell 144,316 shares at $2.4. February 20 '25 |
Similar companies
Read more about Allogene Therapeutics (ALLO) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Allogene Therapeutics?
The Market Cap of Allogene Therapeutics is $258M.
What is the current stock price of Allogene Therapeutics?
Currently, the price of one share of Allogene Therapeutics stock is $1.20.
How can I analyze the ALLO stock price chart for investment decisions?
The ALLO stock price chart above provides a comprehensive visual representation of Allogene Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Allogene Therapeutics shares. Our platform offers an up-to-date ALLO stock price chart, along with technical data analysis and alternative data insights.
Does ALLO offer dividends to its shareholders?
As of our latest update, Allogene Therapeutics (ALLO) does not offer dividends to its shareholders. Investors interested in Allogene Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Allogene Therapeutics?
Some of the similar stocks of Allogene Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.